For folate receptor α (FRα) overexpression in colon cancer, F-PLP/pIL12 treatment significantly inhibits CT26 tumor growth and is safe, accompanied by increased IL-12 expression and IFN-γ secretion in tumor tissues [171]. This evidence concerns the gene IFNG and neoplasm.